Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Neutrexin Patent Expiration

Neutrexin is a drug owned by Medimmune Oncology Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 18, 2018. Details of Neutrexin's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6017922 Thermally stable trimetrexates and processes for producing the same
May, 2018

(6 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Neutrexin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Neutrexin's family patents as well as insights into ongoing legal events on those patents.

Neutrexin's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Neutrexin's generic launch date based on the expiry of its last outstanding patent is estimated to be May 18, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Neutrexin Generics:

There are no approved generic versions for Neutrexin as of now.





About Neutrexin

Neutrexin is a drug owned by Medimmune Oncology Inc. Neutrexin uses Trimetrexate Glucuronate as an active ingredient. Neutrexin was launched by Medimmune Oncology in 1993.

Approval Date:

Neutrexin was approved by FDA for market use on 17 December, 1993.

Active Ingredient:

Neutrexin uses Trimetrexate Glucuronate as the active ingredient. Check out other Drugs and Companies using Trimetrexate Glucuronate ingredient

Dosage:

Neutrexin is available in injectable form for injection use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 200MG BASE/VIAL INJECTABLE Discontinued INJECTION
EQ 25MG BASE/VIAL INJECTABLE Discontinued INJECTION